KalVista Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	Current	FY	FY	FY	FY	FY
Period Ending	Mar '26 Mar 4, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Market Cap	842	685	483	291	313	610
Market Cap Growth	74.50%	41.98%	65.58%	-6.74%	-48.75%	213.22%
Enterprise Value	736.02	470.91	279.54	150.34	154.52	366.81
Last Close Price	16.65	13.77	11.35	8.53	12.73	24.97
PE Ratio	-	-3.73	-3.30	-2.56	-3.79	-10.32
PS Ratio	553.32	-	-	-	-	-
PB Ratio	19.26	7.18	2.34	1.81	1.69	2.37
P/TBV Ratio	-	7.17	2.02	1.48	1.68	1.85
P/FCF Ratio	-	-4.47	-5.41	-3.81	-3.95	-20.16
P/OCF Ratio	-	-4.48	-5.41	-3.87	-4.00	-20.21
EV/Sales Ratio	516.15	-	-	-	-	-
EV/EBITDA Ratio	-	-2.52	-2.00	-1.36	-1.61	-6.39
EV/EBIT Ratio	-	-2.50	-1.99	-1.36	-1.60	-6.33
EV/FCF Ratio	-	-3.07	-3.13	-1.97	-1.95	-12.12
Debt / Equity Ratio	8.80	0.07	0.04	0.05	0.04	0.02
Debt / EBITDA Ratio	-	-0.03	-0.05	-0.07	-0.08	-0.10
Debt / FCF Ratio	-	-0.04	-0.08	-0.11	-0.10	-0.19
Net Debt / Equity Ratio	-9.39	-2.25	-0.98	-0.88	-0.85	-0.94
Net Debt / EBITDA Ratio	-	1.15	1.45	1.28	1.65	4.24
Net Debt / FCF Ratio	-	1.40	2.28	1.85	2.00	8.03
Quick Ratio	7.02	4.92	9.60	11.04	15.58	26.53
Current Ratio	7.22	5.35	9.90	11.46	16.73	27.04
Return on Equity (ROE)	-	-121.50%	-68.90%	-53.69%	-37.23%	-27.13%
Return on Assets (ROA)	-	-78.79%	-67.10%	-57.29%	-40.60%	-31.78%
Return on Invested Capital (ROIC)	-	-26219.94%	-1201.41%	-472.18%	-468.40%	-363.66%
Return on Capital Employed (ROCE)	-	-89.91%	-73.77%	-61.51%	-42.51%	-33.38%
Earnings Yield	-25.74%	-26.80%	-30.31%	-39.04%	-26.39%	-9.69%
FCF Yield	-21.28%	-22.38%	-18.50%	-26.23%	-25.30%	-4.96%
Buyback Yield / Dilution	-	-9.00%	-31.23%	-19.94%	-0.51%	-34.78%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q